1. Family name: Yeşilipek
  2. First names: Akif
  3. Date of birth: September 26th 1956
  4. Nationality: Turkish
  5. Civil Status: Married
  6. Education:
Institution

[ Date from – Date to ]

Degree(s) or Diploma(s) obtained:
1973 – 1980 Degree of MD, in Hacettepe University Samsun School of Medicine, Ankara
1980 – 1984 Residency program in the Department of Pediatrics in Ondokuzmayıs University School of Medicine, Samsun
1984-1989 Pediatrician in Samsun State Hospital, Samsun.
1989-1993 Assist. Prof. in the Department of Pediatric Hematology in

Akdeniz University  School of Medicine, Antalya

1993-1999 Assoc. Prof. in the Department of Pediatric  Hematology, in

Akdeniz University School of Medicine, Antalya

1999-2013 Professor  in the Department of Pediatric Hematology, in

Akdeniz University School of Medicine, Antalya

2014- Professor  in the Department of Pediatric Hematology, in

Bahcesehir University School of Medicine,Istanbul

  1. Language skills: (1 – excellent; 5 – basic)
Language Reading Speaking Writing
Turkish Mother Tongue
English 1 1 1
  1. Membership of professional bodies :
  • Member of Turkish Foundation of Pediatrics
  • Member of Turkish Society of Hematology
  • Member of European Haematology Association
  • Member of Akdeniz Thalassemia Society
  • Member of Akdeniz Hemophilia Society
  • Member of Turkish Pediatric Oncology Group
  • Member of Turkish Pediatric Hematology
  • Member of European Group for Blood and Bone Marrow Transplantation
  • Member of American Society of Hematology
  1. Other skills: Full Computer Literacy
  2. Present position: Professor in the Department of Pediatric Hematology and Director of Pediatric Stem Cell Transplantation Unit
  3. Years within the firm: 30 years
  4. Key qualifications:
  • 30 years of general professional working experience as Lecturer in Akdeniz School of Medicine and Bahcesehir University School of Medicine, Director of Pediatric Stem Cell Transplantation Units, Founding President, Head of Pediatric Department, Head of Pediatric Hematology Department,
  • Extensive experience clinical use of stem cells in children,
  • President of Turkish Pediatric Hematology Society, Akdeniz Thalassemia Society, Akdeniz Hemophilia Society,
  • ASH congress abstract reviewer and chairman of session,
  • EBMT Pediatric Diseases Working Party Board member

 

  1. Specific experience in the region:
Country Dates
Turkey 1984-2014

  1. Professional experience
Date to Location Company Position Description
2014- Turkey Bahcesehir University School of Medicine Professor  in the Department of Pediatric Hematology, Head Mr Yeşilipek worked as Professor at Bahcesehir University School of Medicine and was responsible for;

·          Giving lectures and courses to all students of freshman

·          Preparing of academic courses plan

.      Acting as role of supervisor of students

.      Director of Pediatric Stem Cell Transplantation Units

.     Head of Pediatric Hematology Department

2009-2011 Turkey Turkish Society of Pediatric Hematology President Mr Yeşilipek worked as President at Turkish Society of Pediatric Hematology and was responsible for;

. Attend standing ofmeetings (board , comittee etc.)

. Develop policies and procedures about pediatric hematology

. Manage strategic development,

. Manage physician relations and/or presentation

2002-2008

Turkey Akdeniz University School of Medicine Head of Department of Pediatrics Mr Yeşilipek worked as Head of Department of Pediatrics  at Akdeniz University School of Medicine  and was responsible for;

. Responsible all academical activities of Pediatric Department

. Responsible all educational activities of Department of Pediatrics.XX

1999- 2013 Turkey Akdeniz University School of Medicine Professor  in the Department of Pediatric Hematology, Mr Yeşilipek worked as Professor at Akdeniz University School of Medicine  and was responsible for;

·          Giving lectures and courses to all students of freshman

·          Preparing of academic courses plan

·          Acting as role of supervisor of students

Director of Pediatric Stem Cell Transplantation Unit

1998-2012 Turkey Akdeniz University School of Medicine Head of Pediatric Stem Cell  Transplantation Unit Mr Yeşilipek worked as Head of Pediatric Stem Cell  Transplantation Unit at Akdeniz University School of Medicine  and was responsible for

. All medical activities, treatment and follow ups

1993-1999 Turkey Akdeniz University School of Medicine Assoc. Prof. in the Department of Pediatric Mr Yeşilipek worked as Associate Professor at Akdeniz University School of Medicine and was responsible for;

·          Giving lectures and courses to all students of freshman

1989-1993 Turkey Akdeniz University School of Medicine Assist. Prof. in the Department of Pediatric Hematology Mr Yeşilipek worked as Assistant Professor at Akdeniz University School of Medicine and was responsible for;

•              Giving lectures and courses to all students of freshman

1984- 1989 Turkey Samsun State Hospital Pediatrician Mr Yeşilipek worked as Pediatrician at  Samsun State Hospital and was responsible for;

. Treatment and follow up of children in public hospital

  1. Other relevant information:

Training Courses

  • Torino University, Italy, Clinical observer,

Pediatric Hematology Department – Thalassemia Division

Bone marrow Transplantation Unit, May-June 1992.

  • Royal Free Hospital and School of Medicine, Londra, England

Clinical observer, Hematology and Bone marrow Transplantation Unit,

Agoust – October 1997.

  • Working Party on Paediatric Diseases

European Group for Blood and Marrow Transplantation

Barcelona, 7-9 May 1998.

  • European School of Haematology

The Third ESH-EBMT Postgraduate Training Course on Blood and Bone Marrow Transplantation

Potsdam, Berlin, 6-9 June 1998.

  • European School of Haematology

The Eighth European Tutorial on Haematopathology

  • Londra, 6-10 March 1999.

  • European Council for Accreditation in Hematology

In association with the European School of Hematology

Advenced ICAS-Training Course on Blood Stem Transplantation: State-of-the-Arts, Methods, and Perspectives, Ulm, 10-13, March, 2003.

  • European School of Haematology

The Tenth ESH-EBMT Postgraduate Training Course on Blood and Bone Marrow Transplantation

Warsaw, Poland, 24-28 May 2006.

International Projects

  • NOVAe-MED -an European Project of a New Generation; Innovative e-learning in reparative medicine, European Union Leonardo da Vinci Pilot Projects, BG/05/B/F/PP-166046,  Section responsibility in “Project Governing Committee”. 2005. http://novae-med.bg-id.com (6 th Frame Program).
  • ALL-BFM Stem Cell Transplantation, EBMT Pediatric Disease Working Party
  • International multicentre prospective study, National coordinator.
  • LA-35 PM; Active Drug Surveillance Program for Ferriprox, principal investigator.
  • CORDELIA Cardiac Iron Overload Prevalence, principal investigator,
  • CICL670A2206, Defrasirox, Iron Chelation Therapy, Efficay and Safety, principal investigator.
  • REACH THEM; Chelation therapy in iron overload. Observational study, principal investigator.
  • NN7008-3545 Hemofili A, Pediatric N8 (rFVIII) study, principal investigator.
  • NN7008-3568 Hemofili A Pediatric N8 (rFVIII) study, principal investigator.
  • Recombinant Factor VIIa analog study, principal investigator.
  • Efficacy of FEIBA for acute bleeding and surgical hemostasis in hemofilia A, principal investigator.
  • Post HSCT (CICL670ATR04) Study; Post-transplant iron chelation therapy in patients with thalassemia major, project leader and principal investigator.

 

List of Publications

 

  • YEŞİLİPEK M.Akif , Standart and Low Birth Weight Formula Compared for Effects on Growth of Preterm Infants, The Turkish Journal of Pediatrics, 34:31-36, 1992.

  • YEŞİLİPEK M.Akif, LÜLECİ Güven, OYGÜR Nihal , BERKER Sibel , YEĞİN Olcay, A case of Juvenile Chronic Myeloid Leukemia with XX/XXX Mosoicism, The Turkish Journal of Pediatrics, 34:251-254,1992.

  • YEŞİLİPEK M.Akif ,BİRCAN İffet , OYGÜR Nihal, ERTUĞ Halil , YEĞİN Olcay , GÜR GÜVEN Ayfer, Growth and Sexual Maturation in Children with Beta Thalassemia Major, Haematologica , 78:30-33 , 1993.

  • YEŞİLİPEK M.Akif, LÜLECİ Güven, VELİPAŞAOĞLU Sevtap, BERKER Sibel, YEĞİN Olcay, ” Monosomy 7 Myelodysplasia in childhood”, Acta Haematologica 92: 36-38, 1994.

  • YEŞİLİPEK Akif, KARADOĞAN İhsan, ÜNDAR Levent,  “Bernard-Soulier Syndrome: A Flow cytometric analysis of the membrane GP-Ib expression” , The Turkish Journal of Pediatrics ,    38: 375-379, 1996.

  • YEŞİLİPEK M.Akif, ALICIGÜZEL Yakup, ERTUĞ Halil, YEĞİN Olcay, Glucose 6 Phosphate Dehydrogenase, Glutathione Reductase, Glutathion Peroxidase, Ceruloplasmine, Selenium and Vitamin E Levels in Thalassemia Major, 2nd Meeting of the European Haematology Association, 29 May-1 June 1996, Paris, British Journal of Haematology 93 (Supp 2):35, 1996.

  • YEŞİLİPEK M.Akif, ACAR Gökhan, BAĞCI Hüseyin, YEĞİN Olcay, ATG Therapy Followed by Myelodysplasia with (3,20) (3p13; 20p13), (4,6) (4q31; 6p23) Translocation in a 15 Year Old Boy, 2nd Meeting of the European Haematology Association, 29 May-1 June 1996, Paris, British Journal of Haematology 93 (Supp 2):877, 1996.

  • YEŞİLİPEK M.Akif, YEĞİN Olcay, “Interferon Alfa Therapy for Refractory Idiopathic Thrombocytopenic Purpura in Children ” , The Turkish Journal of Pediatrics, 39: 173-176, 1997.

 

  • YEŞİLİPEK M.Akif, Yeğin Olcay, Ündar Levent, “Carnitine Therapy in Children with Thalassemia Major” Thirty-nineth ASH Annual Meeting, December 5-9, 1997, San Diego,CA, Blood 90 (Suppl 1) : 386, 1997

  • YEŞİLİPEK M.Akif, Yeğin Olcay, “ Carnitine Therapy in Beta Thalassemia Major” ISH- EHA Combined Haematology Congress, Amsterdam, The Nederlands, 4 –8 July 1998, British Journal of Haematology 102 (1): 55, 1998.

  • YEŞİLİPEK M.Akif, Yeğin Olcay, Effects of L-Carnitine in S-Beta Thalassemia, ISH- EHA Combined Haematology Congress, Amsterdam, The Nederlands, 4 –8 July 1998, British Journal of Haematology 102 (1): 55, 1998.

  • YEŞİLİPEK M.Akif, HAZAR Volkan, Yeğin Olcay, L-Carnitine treatment in beta thalassemia major, Acta Haematologica , 100:162-163, 1998

  • HAZAR Volkan, ONGUN Hakan, YEŞİLİPEK M.Akif, YEĞİN Olcay, Failure of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor in a Patient with Kostmann Syndrome, The Turkish Journal of Pediatrics, 41: 117-120, 1999.

 

  • YEŞİLİPEK M.A., HAZAR V., KÜPESİZ A., YEĞİN O. Peripheral stem cell transplantation in haemoglobinopathies, results from a single centre. 5th Annual Meeting of the European Haematology Association Birmingham, UK, 25-28 June 2000, The Hematology Journal Suppl 1(1): 125, 2000.

 

  • YEŞİLİPEK M.Akif, HAZAR Volkan, KÜPESİZ Alphan, YEĞİN Olcay, Peripheral Stem Cell Transplantation in a Child with Amegakaryocytic Thrombocytopenia, Bone Marrow Transplant   , 26 (5) : 569-70, 2000.

  • AKMAN S., BAHAT E., YEŞİLİPEK A., GÜR GÜVEN A. An uncommon cause of hematuria : Factor VII deficiency in two brothers. Pediatric Nephrology 2000; 14: 68.

  • OYGÜR Nihal, TUNGA Mustafa, MUMCU Yelda, YEŞİLİPEK M.Akif, GURA Aşkın, COŞKUN Mesut, YEĞİN Olcay. Thrombopoietin levels of thrombocytopenic term and preterm newborns with infection, Am J Perinatol, Aug;18(5): 279-86, 2001.

  • YEŞİLİPEK M.Akif, HAZAR Volkan, KÜPESİZ Alphan, KIZILÖRS Aytuğ, UĞUZ Ayşen, YEĞİN Olcay. Peripheral blood stem cell transplantation in children with beta thalassemia. Bone Marrow Transplant, 28 (11): 1037-40, 2001 .

  • KESER I., GÜZELOĞLU-KAYIŞLI Ö., YEŞİLİPEK A., ÖZEŞ O.N., LÜLECİ G. Hb Antalya  Codons 3-5 ( Leu-Thr-ProSer-Asp-Ser).. A new unstable variant leading to chronic macrocytic anemia and high HbA2. Hemoglobin 25(4) : 369-373,2001.

  • BİRBEN E., ÖNER C., ÖNER R., MERGEN H., YEŞİLİPEK M.A., GÜMRÜK F., GÜRGEY A., ALTAY Ç. Severe β Thalassemia in frameshift Codon 6 (-A) Homozygotes: Effects of haplotype on phenotype. Hemoglobin 25(4): 441-445, 2001.

  • HAZAR V, COLAK D, KUPESİZ OA, OGUNÇ D, OGUNÇ G, GUNTEKİN M, YESİLİPEK MA CMV infection in CMV seropositve children following peripheral blood stem cell transplantation , Bone Marrow Transplant 30: P78 Suppl. 1 NOV 2002.

  • KARAUZUM SB, HAZAR V, AÇIKBAŞ I, GELEN T, YEŞİLİPEK MA, LULECİ G. Existence of acute lymphoblastic leukemia and osteosarcoma in a child, J Pediat Hematol Onc 24 (7): 572-574 OCT 2002.

  • KARAUZUM SB, CETİN Z, KUPESİZ A, HAZAR V, TANIR F, YESİLİPEK A, LULECİ G. Complex chromosomal abnormalities of diepoxybutane unresponsive fanconi anemia with a lethal acute myeloid leukemia outcome, Int J Cancer : 271-271 Suppl. 13 2002.

  • SAVAŞ B., TANYEL E., BOZCUK HS., YESİLİPEK, KARADOGAN İ., KUPESİZ A., KURTOGLU E., UNDAR L. Using MTT in vitro drug sensitivity test for the prediction of chemotherapy failure of leukemia patients. Annals of Oncology Vol 13, Supp 5, 2002

  • SARGIN CF, AYDEMİR AEM, NAL N, KESER I, YEŞİLİPEK A, Luleci G. A rare mutation of beta-globin gene (IVS 2-849 A -> G) at Exon 2-intron 2 splice site in a Turkish patient with beta-thalassaemia major European Journal of human genetics 10: 204-204 Suppl. 1 MAY 2002

  • HAZAR V, KANSOY S, KUPESİZ A, AKSOYLAR S, KANTAR M, YESİLİPEK Outcomes of cytomegalovirus antigenemia following peripheral blood stem cell transplantation in high-risk pediatric patients, Bone Marrow Transplant 31: S91-S92 Suppl. 1 MAR 2003.

  • KUPESİZ A, KIZILORS A, ASLAN A, BONEVAL C, HAZAR V, YESİLİPEK Feasibility and safety of peripheral blood stem cell collection in children: a single center experience, Bone Marrow Transplant 31: S252-S252 Suppl. 1 MAR 2003.

  • YAKUT S., BERKER KARAUZUM S., KUPESIZ A., HAZAR V., YESILIPEK A., LULECI G. Follow-up of bone marrow transplantation success by FISH. European Journal of Human Genetics Vol:11, Supp:1, May 2003.

  • MANGUOGLU AE., BERKER KARAUZUM S., YAKUT S., CETIN Z., NAl N., KUPESIZ A., HAZAR V., YESILIPEK A., LULECI G. Determination of chromosome aberrations by cytogenetics, FISH and molecular (RT-PCR) analysis in childhood hematological malignancies. European Journal of Human Genetics Vol:11, Supp:1, May 2003.

  • BILGEN T., BERKER KARAUZUM S., KARADOGAN I., UNDAR L., UGUR A., KUPESIZ A., HAZAR V., YESILIPEK A., LULECI G. Is FISH technique adequate on its own in detection of chromosomal alterations in hematological malignancies? European Journal of Human Genetics Vol:11, Supp:1, May 2003.

  • YEŞILIPEK MA., HAZAR V, KÜPESİZ A, Peripheral Stem Cell Transplantation in Childhood, a center experience. Blood 102: 5586,2003.

  • KUPESIZ A, TEZCAN G, HAZAR V, YESİLİPEK ATG as a part of the preparative regimen for pediatric allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 33:S225, Suppl 2004.

  • HAZAR V, KANSOY S, KUPESIZ A, AKSOYLAR S, KANTAR M, YEŞİLİPEK A. High dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral stem cell transplantation. Bone Marrow Transplant 33 : 931-935, 2004.

  • KESER I., SANLIOGLU A.D., MANGUOGLU E., GUZELOGLU KAYISLI O., NAL N., SARGIN F., YESILIPEK A., SIMSEK M., MENDILCIOGLU I., CANATAN D., LULECI G. Moleculer Analysis of Beta-Thalassemia in Antalya. Acta Haematologica, 111:205-210, 2004.

  • HAZAR, Z.BERBER, E.PEŞTERELI, M.COŞKUN, A.YEŞILIPEK, G.KARPUZOĞLU, O.YEGIN. Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies. Pediatric Hematology and Oncology, 22: 247-256, 2005.

  • TEZCAN, A.KÜPESIZ, A.YEŞILIPEK, V.HAZAR, GD AKSU, C.ÖZKAYNAK, G.ÖZBILIM. Embryonic rhabdomyosarcoma presenting as endobronchial tumor in an adolescent. Pediatric Blood and Cancer, 44, 689-690, 2005.

  • ÇETIN,S.BERKER KARAÜZÜM,A.KÜPESIZ,V.HAZAR, M.A.YEŞILIPEK, G.LÜLECI. Lethal AML after stem cell transplantation in a child with DEB unresponsive Fanconi anemia. Haema,8:136-139, 2005.

  • Ö.GÜZELOGLU-KAYIŞLI, İ.KESER, O.N.ÖZEŞ, D.CANATAN, A.YEŞILIPEK, G.LÜLECI. Compound heterozygosity for two beta chain variants: the mildly unstable Hb Tyne (codon 5 Pro— Ser) and HbS (codon 6 Glu–Val) . Turk J Haematol, 22:37-40, 2005 .

  • SARGIN CF, NAL N, MANGUOGLU AE, KESER I, MENDILCIOGLU I, YESILIPEK A, LULECI G. The phenotypic effect of Hb G-Coushatta [beta22 (B4) Glu-Ala] and association with IVS.II.1(G-A)inaTurkishfamily. Genet Couns. 2005;16(3):307-8.

  • NAL, A.E.MANGUOGLU, C.F. SARGIN, İ.KESER, A. KÜPESIZ, A.YEŞILIPEK, G.LÜLECI. Two rare mutations in Turkey:IVS.130 (G-C) and IVS 848 (C-A). Clinical and Laboratory Hematology, 27:274-277, 2005.

  • YESILIPEK, Z.OZTURK, S.KARAUZUM, G.TEZCAN, A.KUPESIZ, V.HAZAR. Mixed chimerism after peripheral blood stem cell transplantation in thalassemia major. Bone Marrow Transplantation, 35, S356-S357, Suppl 2, 2005.

  • TEZCAN, A.KUPESIZ, Z.OZTURK, V.HAZAR, A.YESILIPEK. Use of granulocyte colony stimulating factor after allogeneic peripheral blood stem cell transplantation in children: single-center experience. Bone Marrow Transplantation, 35, S106, Suppl 2, 2005.

  • YESILIPEK, V.HAZAR, A.KUPESIZ,G.TEZCAN, Z.OZTURK, A.UGUZ, O.YEGIN. Allogeneic peripheral blood stem cell transplantation in children. Bone Marrow Transplantation, 35, S363, Suppl 2, 2005.

  • DÜNDAR, A.KÜPESIZ, S.ÖZLEM, E. GILGIL, T.TUNCER, A.YEŞILIPEK. Bone metabolism and mineral density in patients with beta-thalassemia major. Annals of The Rheumatic Diseases, 64,S360 , Suppl 3, 2005.

  • KUPESIZ O.A., TEZCAN G., HAZAR V., YESILIPEK M.A. Peripheral Blood Stem Cell Transplantation in Fanconi Aplastic Anemia: Report of ten cases. Blood, 106(11):5310 (Suppl), 2005.

  • TEZCAN G., KUPESIZ A., UYGUN V., HAZAR V., YESILIPEK M.A. Use of Granulocyte Colony-Stimulating Factor After Allogeneic Peripheral Stem Cell Transplantation in Children with Thalassemia Major: Single center experience. Blood, 106(11):5310 (Suppl), 2005.

  • HAZAR V, UGUR A, COLAK D, SABA R, TEZCAN G, KUPESIZ A, KARADOGAN I, GULTEKIN M, YESILIPEK A, UNDAR L. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovirtreatment. Jpn J Infect Dis. 2006 Aug;59(4):216-21.

  • TEZCAN G, HAZAR V, UYGUN V, KUPESIZ A, YESILIPEK A. Unrelated bone marrow transplantation in a child with high-risk anaplastic large cell lymphoma: case report. Bone Marrow Transplant 37: S346-S346 Suppl. 1, 2006.

 

  • YESILIPEK MA. Stem cell transplantation in hemoglobinopathies. Hemoglobin 2007;31(2):251-6.

  • KESER I, MANGUOGLU E, KAYİSLİ O, YESİLİPEK A, LULECİ G. Combination of Hb Knossos [Cod 27 (G-T)] and IVSII-745 (C-G) in a Turkish patient with beta-thalassemia major. Genet Test. 2007 Fall;11(3):228-30.
  • DUNDAR U, KUPESİZ A, OZDEM S, GİLGİL E, TUNCER T, YESİLİPEK A, GULTEKİN M. Bone metabolism and mineral density in patients with beta-thalassemia major. Saudi Med J. 2007 Sep;28(9):1425-9.

  • ARTAC H , COSKUN M , KARADOGAN I , YEGIN O , YESILIPEK A. Transferrin receptor in proliferation of T lymphocytes in infants with iron deficiency. International Journal Of Laboratory Hematology 29 (4): 310-315 Aug 2007.

  • KUTLUK T, YESILIPEK A. Pediatric Tumor Registry For 2002-2005 In Turkey. Journal Of Pediatric Hematology Oncology 29: S12-S13 Suppl. 1 Jun 2007.

  • OZDEM S , KUPESIZ A , YESILIPEK A. Plasma Homocysteine Levels In Patients With Beta-Thalassemia Major.  Scand J Clin Lab Invest. 2008;68(2):134-9.

  • KARDELEN F, TEZCAN G, AKCURIN G, ERTUG H, YESILIPEK A. Heart rate variability in patients with thalassemia major. Pediatr Cardiol. 2008 Sep;29(5):935-9. Epub 2008 Jun 13.

  • YESİLİPEK MA, TEZCAN G, GERMESHAUSEN M, KUPESİZ A, UYGUN V, HAZAR V. Unrelated cord blood transplantation in children with severe congenital neutropenia. Pediatr Transplant. 2008 Sep 26. [Epub ahead of print].

  • HAZAR V, GUNGOR O, GUVEN AG, AYDİN F, AKBAS H, GUNGOR F, TEZCAN G, AKMAN S, YESİLİPEK Renal function after hematopoietic stem cell transplantation in children. Pediatr Blood Cancer. 2009 Aug;53(2):197-202.

  • AKAY A, DRAGOMIR A, YARDIMCI A, CANATAN D, YESILIPEK A, POGUE B. A Data-Mining Approach for Investigating Social and Economic Geographical Dynamics of ss-thalassemia’s Spread. IEEE Trans Inf Technol Biomed. 2009;13(5):774-780.

  • DURSUN O, ERIŞIR S, YEŞILIPEK A. Visceral childhood leishmaniasis in southern Turkey: experience of twenty years. Turk J Pediatr. 2009 Jan-Feb;51(1):1-5.

  • UYGUN V, KARASU GT, OGUNC D, YESİLİPEK A, HAZAR V. Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: A randomized and open-label study. Pediatr Blood Cancer. 2009;53:610-614.

  • CESARO S, HİRSCH HH, FARACİ M, OWOC-LEMPACH J, BELTRAME A, TENDAS A, BALTADAKİS I, DALLE JH, KOC Y, TOPORSKİ J, STYCZYNSKİ J, YESİLİPEK MA, HEİNZ W, CANİGLİA M, RASCON J, FAUSER AA, MİCHALLET M, LOPEZ-CORRAL L, NEUBURGER S, TRİDELLO G, EİNSELE H; European Group for Blood and Marrow Transplantation. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis. 2009 Jul 15;49(2):233-40.

  • DURSUN O, HAZAR V, KARASU GT, UYGUN V, TOSUN O, YESILIPEK A. Prognostic factors in pediatric cancer patients admitted to the pediatric intensive care unit. J Pediatr Hematol Oncol. 2009 Jul;31(7):481-4.

  • KUTLUK T, YESILIPEK MA. Turkısh Natıonal Pedıatrıc Cancer Regıstry 2002-2008 (Turkısh Pedıatrıc Oncology Group And Turkısh Pedıatrıc Hematology Socıety). Pedıatrıc Blood & Cancer.  2009: 53(5);851.

  • HAZAR V , UYGUN V , KARASU GT , KAZİK M , KUPESİZ A , YESILIPEK A. The Results Of ALL-BFM 95 Based Protocols. A Sıngle Center Experıence. Pedıatrıc Blood & Cancer, 2009:53 (5);773-774.

  • KESER I, YESILIPEK A,CANATAN D, et al. Abnormal Hemoglobins Associated With The Beta-Globin Gene In Antalya Province, Turkey. Turkish Journal Of Medical Sciences 2010;40(1):127-131.

  • UYGUN V.; AKCAN M.; KARASU G.; et al. Haematopoietic stem cell transplantation activity and trends of a single paediatric transplantation centre. BONE MARROW TRANSPLANTATION  2010; 45: Suppl. 2, S275.

  • AYDIN F, TEZCAN G, GUNGOR, et al. Can serum cystatin C reflect the glomerular filtration rate accurately in pediatric patients under chemotherapeutic treatment? A comparative study with Tc-99m DTPA two-plasma sample method . NUCLEAR MEDICINE COMMUNICATIONS 2010;31(4):301-306.

  • KAVAKLI K, YESILIPEK A, ANTMEN B, et al. The value of early treatment in patients with haemophilia and inhibitors. HAEMOPHILIA 2010;16 (3): 487-494.

  • YESILIPEK M. A, KARASU G, KAZIK M, et al. Posttransplant Oral Iron-Chelatıng Therapy In Patients With Beta-Thalassemıa Major Pedıatrıc Hematology and Oncology 2010; 27;(5): 374-379.

  • HAZAR V, KARASU G, UYGUN V et al. Childhood Acute Lymphoblastic Leukemia in Turkey: Factors Influencing Treatment and Outcome A Single Center Experience. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 2010;: 32(8)   P: E317-E322.

  • YESİLİPEK MA, KARASU G, ERÇELEN N, UYGUN V, AKCAN M, KUPESİZ A, HAZAR V. Successful hematopoietic SCT from non-identical twins to two sisters with β-thalassemia major by using preimplantation genetic diagnosis and HLA typing. Bone Marrow Transplant. 2011 Dec;46(12):1581-2.

  • KARASU GT, YESİLİPEK MA, KARAUZUM SB, UYGUN V, MANGUOGLU E, KUPESİZ A, HAZAR V. The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation. Pediatr Blood Cancer. 2012 Mar;58(3):453-8.

  • ZÜLFİKAR B, AYDOGAN G, SALCİOGLU Z, et al ; FEIBA Investigators Team. Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey.Hemophilia, 2012, 18 (3) pp 383-91.

  • STYCZYNSKİ J, BALDUZZİ A, GİL L, LABOPİN M, HAMLADJİ RM, MARKTEL S, YESİLİPEK MA, FAGİOLİ F, EHLERT K, MATULOVA M, DALLE JH, WACHOWİAK J, MİANO M, MESSİNA C, DİAZ MA, VERMYLEN C, EYRİCH M, BADELL I, DREGER P, GOZDZİK J, HUTT D, RASCON J, DİNİ G, PETERS C; European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party. Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. Blood. 2012 Mar 22;119(12):2935-42.

  • FERNANDES JF, ROCHA V, LABOPİN M, et al. Eurocord and Inborn Errors Working Party of European Group for Blood and Marrow Transplantation.Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood. 2012 Mar 22;119(12):2949-55.

  • AYDİNOK Y, UNAL S, OYMAK Y, VERGİN C, TÜRKER ZD, YİLDİZ D, YESİLİPEK Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload. Eur J Haematol. 2012 May;88(5):431-8.

  • CETİN Z, YAKUT S, KARADOGAN I, KUPESİZ A, TİMURAGAOGLU A, SALİM O, TEZCAN G, ALANOGLU G, OZBALCİ D, HAZAR V, YESİLİPEK MA, UNDAR L, LULECİ G, BERKER S. Aberrations of chromosomes 9 and 22 in acute lymphoblastic leukemia cases detected by ES-fluorescence in situ hybridization. Genet Test Mol Biomarkers. 2012 May;16(5):318-23.

  • DE PAULA EV, KAVAKLİ K, MAHLANGU J, ET AL, ; 1804 (ADEPT(TM)1) INVESTİGATORS. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9.

  • UYGUN V, TAYFUN F, AKCAN M, KARASU GT, KUPESİZ A, HAZAR V, YEŞİLİPEK A. Quality of life assessment in hematopoietic stem cell transplantation performed on thalassemia major patients. Pediatr Hematol Oncol. 2012 Aug;29(5):461-71.

  • YESİLİPEK AM, AKCAN M, KARASU G, UYGUN V, KUPESİZ A, HAZAR V. Successful unrelated bone marrow transplantation in two siblings with alpha-mannosidosis. Pediatr Transplant. 2012 Nov;16(7):779-82.

  • EFE E, IŞLER A, SARVAN S, BAŞER H, YEŞİLİPEK A. Complementary and alternative medicine use in children with thalassaemia. J Clin Nurs. 2012 Aug 21.

  • YESİLİPEK MA, ERTEM M, CETİN M, ÖNİZ H, KANSOY S, TANYELİ A, ANAK S, KUREKCİ E, HAZAR V. HLA-matched family hematopoetic stem cell transplantation in children with beta thalassemia major: the experience of the Turkish Pediatric Bone Marrow Transplantation Group. Pediatr Transplant. 2012 Dec;16(8):846-51.

  • POWELL J, MARTİNOWİTZ U, WİNDYGA J, ET AL; LIPLONG STUDY INVESTİGATORS.Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.Thromb Haemost. 2012 Nov;108(5):913-22.

  • DAİKELER T, LABOPİN M, RUGGERİ A, CROTTA A, ABİNUN M, HUSSEİN AA, CARLSON K, CORNİLLON J, DİEZ-MARTİN JL, GANDEMER V, FARACİ M, LİNDEMANS C, O’MEARA A, MİALOU V, RENARD M, SEDLACEK P, SİRVENT A, SOCİÉ G, SORA F, VAROTTO S, SANZ J, VOSWİNKEL J, VORA A, YESİLİPEK MA, HERR AL, GLUCKMAN E, FARGE D, ROCHA V. New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of EBMT. 2013 Feb 7;121(6):1059-64.
  • ROVÓ A, ALJURF M, CHİODİ S, et al; Late Effects Working Party of the EBMT. Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2013 Mar;98(3):339-45